The present disclosure relates generally to a blood transfer device. More particularly, the present disclosure relates to a blood transfer device, a blood transfer and testing system, a lancet and blood transfer device, and a method of loading an anticoagulant.
Blood sampling is a common health care procedure involving the withdrawal of at least a drop of blood from a patient. Blood samples are commonly taken from hospitalized, homecare, and emergency room patients either by finger stick, heel stick, or venipuncture. Once collected, blood samples may be analyzed to obtain medically useful information including, for example, chemical composition, hematology, and coagulation.
Blood tests determine the physiological and biochemical states of the patient, such as disease, mineral content, drug effectiveness, and organ function. Blood tests may be performed in a clinical laboratory or at the point-of-care near the patient.
The present disclosure provides a blood transfer device adapted to receive a blood sample. The blood transfer device includes a housing having a first end, a second end, a sidewall extending therebetween, and an actuation member movable between a first position and a second position. A deformable material is disposed within the housing and is deformable from an initial position in which the material is adapted to hold the blood sample to a deformed position in which a portion of the blood sample is released from the material. A viscoelastic member is disposed within the housing between the material and the sidewall of the housing and between the material and the actuation member. The viscoelastic member is engaged with the actuation member and the material such that movement of the actuation member from the first position to the second position exerts a force on the viscoelastic member which redistributes the force evenly over the material and deforms the material from the initial position to the deformed position.
In accordance with an embodiment of the present invention, a specimen transfer device adapted to receive a sample includes a housing having a first end, a second end, a sidewall extending therebetween, and an actuation member movable between a first position and a second position. The device further includes a deformable material disposed within the housing, in which the material is deformable from an initial position in which the material is adapted to contain the sample, to a deformed position in which at least a portion of the sample is released from the material. The device also includes a viscoelastic member disposed within the housing between the material and the sidewall of the housing and between the material and the actuation member. The viscoelastic member is engaged with the actuation member and the material such that movement of the actuation member from the first position to the second position exerts a force on the viscoelastic member which deforms the material from the initial position to the deformed position.
In certain configurations, the deformable material includes pores. The device may also include a dry anticoagulant powder disposed within the pores of the material. The housing may also include a dispensing tip at the first end. Optimally, the housing includes a valve disposed within the dispensing tip, with the valve being transitionable between a closed position and an open position. With the material in the deformed position and the valve in the open position, the at least a portion of the sample may be released from the material and may flow through the dispensing tip.
In certain configurations, the viscoelastic member has a viscoelastic member hardness. The actuation member may also have an actuation member hardness. In certain configurations, the viscoelastic member hardness is less than the actuation member hardness. The actuation member may be located at the second end of the housing. Optionally, the actuation member may be a push button, and the sample may be blood.
In accordance with another embodiment of the present invention, a specimen transfer and testing system may include a specimen transfer device adapted to receive a sample. The specimen transfer device may include a housing having a first end, a second end, a sidewall extending therebetween, a dispensing tip at the first end, an actuation member at the second end, and a valve disposed within the dispensing tip. The actuation member may be movable between a first position and a second position, and the valve may be transitionable between a closed position and an open position. The specimen transfer device may also include a deformable material having pores and disposed within the housing, with the material deformable from an initial position in which the material is adapted to contain the sample to a deformed position in which at least a portion of the sample is released from the material. The specimen transfer device may also include a viscoelastic member disposed within the housing between the material and the sidewall of the housing and between the material and the actuation member. The viscoelastic member may be engaged with the actuation member and the material such that movement of the actuation member from the first position to the second position exerts a force on the viscoelastic member which deforms the material from the initial position to the deformed position. With the material in the deformed position and the valve in the open position, the portion of the sample released from the material may flow through the dispensing tip. The specimen transfer and testing system may also include a sample testing device having a receiving port adapted to receive the dispensing tip of the specimen transfer device for closed transfer of at least a portion of the sample from the specimen transfer device to the sample testing device.
In certain configurations, the specimen transfer device further includes a dry anticoagulant powder within the pores of the material. The viscoelastic member may have a viscoelastic member hardness, the actuation member may have an actuation member hardness, and the viscoelastic member hardness may be less than the actuation member hardness. In certain configurations, the actuation member is a push button. In other configurations, the specimen is blood.
In accordance with yet another embodiment of the present invention, a lancet and specimen transfer device includes a lancet housing having a forward end, a rearward end, and a puncturing element, the puncturing element at least partially disposed within the lancet housing and adapted for movement between a pre-actuated position wherein the puncturing element is retained within the lancet housing and a puncturing position wherein at least a portion of the puncturing element extends through the forward end of the lancet housing. The lancet and specimen transfer device further includes a specimen transfer device engageable with the rearward end of the lancet housing.
In accordance with another embodiment of the present invention, a blood transfer device adapted to receive a blood sample includes a housing having a first end, a second end, and an actuation member transitionable between a first position and a second position. The blood transfer device further includes an open cell foam material disposed within the housing and having a dry anticoagulant powder therein.
In certain configurations, the blood transfer device also includes a capillary tube in fluid communication with the open cell foam material. The housing may also include a lid movable between a closed position in which the open cell foam material is sealed within the housing and an open position in which a portion of the open cell foam material is exposed. The capillary tube may be adapted to receive the blood sample after the blood sample is mixed with the dry anticoagulant powder within the open cell foam material. The capillary tube may include a dispensing tip.
Movement of the actuation member from the first position to the second position may dispense the blood sample through the dispensing tip of the capillary tube. The first capillary tube may be disposed between the first end of the housing and the open cell foam material. The device may also include a second capillary tube in fluid communication with the open cell foam material, with the second capillary tube disposed between the second end of the housing and the open cell foam material. The second capillary tube may be adapted to receive the blood sample after the blood sample is mixed with the dry anticoagulant powder within the open cell foam material. Movement of the actuation member from the first position to the second position may dispense the blood sample through a dispensing tip of the second capillary tube. At least one of an internal surface of the first capillary tube and an internal surface of the second capillary tube may include an anticoagulant coating. The first capillary tube and the second capillary tube may have different lengths. Optionally, the first capillary tube and the second capillary tube may have different internal diameters.
The above-mentioned and other features and advantages of this disclosure, and the manner of attaining them, will become more apparent and the disclosure itself will be better understood by reference to the following descriptions of embodiments of the disclosure taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the disclosure, and such exemplifications are not to be construed as limiting the scope of the disclosure in any manner.
The following description is provided to enable those skilled in the art to make and use the described embodiments contemplated for carrying out the invention. Various modifications, equivalents, variations, and alternatives, however, will remain readily apparent to those skilled in the art. Any and all such modifications, variations, equivalents, and alternatives are intended to fall within the spirit and scope of the present invention.
For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, “lateral”, “longitudinal”, and derivatives thereof shall relate to the invention as it is oriented in the drawing figures. However, it is to be understood that the invention may assume various alternative variations, except where expressly specified to the contrary. It is also to be understood that the specific devices illustrated in the attached drawings, and described in the following specification, are simply exemplary embodiments of the invention. Hence, specific dimensions and other physical characteristics related to the embodiments disclosed herein are not to be considered as limiting.
In one embodiment, housing 14 includes a first end 20, a second end 22, a sidewall 24 extending therebetween, a dispensing tip 26 at the first end 20, an actuation member 28 at the second end 22, a valve 30, a cap 32, and a finger flange 34.
The blood transfer device 10 may include an actuation member 28 that is movable between a first position and a second position. In one embodiment, the actuation member 28 is located at the second end 22 of the housing 14. In one embodiment, the actuation member 28 is a push button. The actuation member has an actuation member hardness.
The blood transfer device 10 may include a cap 32 for protectively covering the blood transfer device 10 prior to use thereof. In one embodiment, the cap 32 protectively covers the dispensing tip 26 of the blood transfer device 10 prior to use thereof.
The blood transfer device 10 may include a valve 30 that is transitionable between a closed position and an open position. In one embodiment, the valve 30 is disposed within the dispensing tip 26. With the valve 30 in an open position, a portion of the blood sample 12 that is released from the material 16 is able to flow through the dispensing tip 26. In one embodiment, a portion of the blood sample 12 that is released from the material 16 is able to flow through the dispensing tip 26 to a blood testing device 60. With the valve 30 in a closed position, no portion of the blood sample 12 is able to flow from the blood transfer device 10.
Referring to
In one embodiment, material 16 includes pores 40 (
In one embodiment, the material 16 is a sponge material. In one embodiment, the material 16 is an open cell foam. In one embodiment, the open cell foam is treated with an anticoagulant, as described in detail below, to form a dry anticoagulant powder finely distributed throughout the pores 40 of the material 16. The open cell foam may be loaded with a blood sample. The blood gets soaked into the open cell foam based on capillary principles. As the blood is loaded into the open cell foam, the blood is exposed to the anticoagulant powder throughout the internal micro pore structure of the open cell foam. Once the open cell foam is loaded with the blood, the open cell foam may be deformed, e.g., compressed, to squeeze-out a stabilized blood sample. In one embodiment, the stabilized blood sample may be transferred to a diagnostic instrument such as a blood testing device, a point-of-care testing device, or similar analytical device.
In one embodiment, the material 16 is a soft deformable open cell foam that is inert to blood. In one embodiment, the open cell foam may be a melamine foam, such as Basotect® foam commercially available from BASF. In another embodiment, the open cell foam may consist of a formaldehyde-melamine-sodium bisulfite copolymer. The open cell foam may be a flexible, hydrophilic open cell foam that is resistant to heat and many organic solvents. In one embodiment, the open cell foam may be a sponge material.
A method of loading an anticoagulant to a material 16 having pores 40 will now be discussed. In one embodiment, the method includes soaking the material 16 in a liquid solution of the anticoagulant and water; evaporating the water of the liquid solution; and forming a dry anticoagulant powder 42 within the pores 40 of the material 16.
The method of the present disclosure enables precisely controlled loading of an anticoagulant into the material 16 by soaking it with an anticoagulant and water solution and then drying the material 16 to form a finely distributed dry anticoagulant powder 42 throughout the pores 40 of the material 16.
Anticoagulants such as Heparin or EDTA (Ethylene Diamine Tetra Acetic Acid) as well as other blood stabilization agents could be introduced into the material 16 as a liquid solution by soaking the material 16 in the liquid solution of a desired concentration. After evaporating the liquid phase, e.g., evaporating the water from a water and Heparin solution, a dry anticoagulant powder may be formed and finely distributed throughout the internal structure of the material 16. For example, the dry anticoagulant powder may be finely distributed throughout the pores 40 of the material 16. In a similar manner, the material 16 could be treated to provide a hydrophobic, hydrophilic, or reactive internal pore surface.
In one embodiment, the viscoelastic member 18 is disposed within the housing 14 of the blood transfer device 10 between the material 16 and the sidewall 24 of the housing 14 and between the material 16 and the actuation member 28. For example, referring to
Viscoelastic member 18 of an exemplary embodiment is preferably made of a pliable material, such as a soft elastomer, for example. In one exemplary embodiment, viscoelastic member 18 is made from a viscoelastic material such as silicone or a thermoplastic elastomer (TPE). The viscoelastic member 18 serves as an intermediate member between the material 16 and the rigid surrounding components, e.g., the sidewall 24 of the housing 14 and the actuation member 28. In one embodiment, the viscoelastic member 18 serves as a damper or a soft viscoelastic damper. The viscoelastic member 18 uniformly redistributes the external imposed strain to the material 16 via the actuation member 28 as described below. In this manner, the viscoelastic member 18 minimizes blood hemolysis due to localized excessive deformation of the material 16. Additionally, the viscoelastic member 18 controls the speed of the deformation of the material 16 and mitigates the rate of the force applied to deform the material 16 via the actuation member 28.
The viscoelastic member 18 has a viscoelastic member hardness. The viscoelastic member hardness is less than the actuation member hardness. In one embodiment, the viscoelastic member hardness of the material that forms viscoelastic member 18 may have a hardness value on the Shore Durometer scale in the type A range for soft elastomers. In one exemplary embodiment, viscoelastic member 18 has a hardness of approximately Shore A 5.
The blood transfer device 10 may include a finger flange 34. When it is desired to expel or deliver a portion of the blood sample 12 from the material 16, the blood transfer device 10 is grasped with the user's thumb on the actuation member 28 and with the user's fingers extending around the finger flange 34. In this manner, the blood transfer device 10 is grasped by a user in a well-known and well recognized manner similar to the operation of a conventional hypodermic syringe. Next, the user effects a squeezing movement between the thumb on the actuation member 28 and the fingers grasping the finger flange 34, thereby causing the actuation member 28 to move in a direction generally along arrow A (
The viscoelastic member 18 is engaged with the actuation member 28 and the material 16 such that movement of the actuation member 28 from the first position to the second position exerts a force on the viscoelastic member 18 which redistributes the force evenly over the material 16 and deforms the material 16 from the initial position to the deformed position. In this manner, the viscoelastic member 18 minimizes blood hemolysis due to localized excessive deformation of the material 16. Additionally, the viscoelastic member 18 controls the speed of the deformation of the material 16 and mitigates the rate of the force applied to deform the material 16 via the actuation member 28.
With the material 16 in the deformed position and the valve 30 of the housing 14 in the open position, the portion of the blood sample 12 released from the material 16 is able to flow through the dispensing tip 26.
Referring to
During the use of blood transfer device 10A, a lancet device can be used to lance a skin surface S of a patient. Next, the cap 72 is moved to the open position to expose the material 16A. The blood transfer device 10A is then positioned such that the material 16A is placed adjacent a punctured skin surface S of a patient so that the blood sample 12 can be transferred to the material 16A. For example, the material 16A may touch the punctured skin surface S to soak up the blood sample 12. As the blood 12 is loaded into the material 16A, the blood 12 is exposed to the anticoagulant powder throughout the internal micro pore structure of the material 16A. Once the material 16A is loaded with the blood 12, the cap 72 is moved to the closed position and the material 16A is deformed, e.g., compressed, to squeeze out a stabilized blood sample 12. In one embodiment, the stabilized blood sample 12 may be transferred to a diagnostic instrument such as a blood testing device 60A.
Referring to
During the use of blood transfer device 10B, a lancet device 100 can be used to lance a skin surface S of a patient. Next, the blood transfer device 10B is moved to the open position to expose the material 16B within the chamber 86. The blood transfer device 10B is then positioned such that the material 16B is placed adjacent a punctured skin surface S of a patient so that the blood sample 12 can be transferred to the material 16B. For example, the material 16B may touch the punctured skin surface S to soak up the blood sample 12. As the blood 12 is loaded into the material 16B, the blood 12 is exposed to the anticoagulant powder throughout the internal micro pore structure of the material 16B. Once the material 16B is loaded with the blood 12, the blood transfer device 10B is moved to the closed position and the material 16B is deformed, e.g., compressed, to squeeze out a stabilized blood sample 12. For example, the blood transfer device 10B can be squeezed so that the protruding element 88 deforms the material 16B thereby squeezing a stabilized blood sample 12 through the sterile cap 89. In one embodiment, the stabilized blood sample 12 may be transferred to a diagnostic instrument such as a blood testing device 60B.
Referring to
During the use of blood transfer device 10C, a lancet device can be used to lance a skin surface S of a patient. Next, the second body portion 92 is removed from the first body portion 90 to open the blood transfer device 10C and expose the material 16C within the chamber 94. The blood transfer device 10C is then positioned such that the material 16C is placed adjacent a punctured skin surface S of a patient so that the blood sample 12 can be transferred to the material 16C. For example, the material 16C may touch the punctured skin surface S to soak up the blood sample 12. As the blood 12 is loaded into the material 16C, the blood 12 is exposed to the anticoagulant powder throughout the internal micro pore structure of the material 16C. Once the material 16C is loaded with the blood 12, the second body portion 92 is connected to the first body portion 90 to close the blood transfer device 10C and the material 16C is deformed, e.g., compressed, to squeeze out a stabilized blood sample 12. For example, the slide button 96 can be moved from the first position to the second position to compress the material 16C and squeeze a stabilized blood sample 12 through the dispensing tip 26C. In one embodiment, the stabilized blood sample 12 may be transferred to a diagnostic instrument such as a blood testing device 60C, as shown in
In one embodiment, lancet device 120 includes a lancet housing 122 having a forward end 124 and a rearward end 126, a lancet structure 128 having a puncturing element 130, a protective cover 132, and a grip portion 134. In one embodiment, the lancet device 120 is a contact activated lancet device. The lancet device 120 may include the protective cover 132 for protectively covering the lancet device 120 prior to use thereof. The lancet housing 122 may include the grip portion 134 to generally improve the grip between the lancet housing 122 and the user's fingertips.
The lancet structure 128 is at least partially disposed within the lancet housing 122 and is adapted for movement between a pre-actuated position wherein the puncturing element 130 is retained within the lancet housing 122 and a puncturing position wherein at least a portion of the puncturing element 130 extends through the forward end 124 of the lancet housing 122.
Referring to
During the use of lancet and blood transfer device 110, the lancet device 120 can be used to lance a skin surface S of a patient. Next, the cap 144 of the blood transfer device 10D is moved to the open position to expose the material 16D within the chamber 140.
The lancet and blood transfer device 110 is then positioned such that the material 16D is placed adjacent a punctured skin surface S of a patient so that the blood sample 12 can be transferred to the material 16D. For example, the material 16D may touch the punctured skin surface S to soak up the blood sample 12. As the blood 12 is loaded into the material 16D, the blood 12 is exposed to the anticoagulant powder throughout the internal micro pore structure of the material 16D. Once the material 16D is loaded with the blood 12, the cap 144 is moved to the closed position to close the blood transfer device 10D and the material 16D is deformed, e.g., compressed, to squeeze out a stabilized blood sample 12. For example, the push button 142 can be moved from the first position to the second position to compress the material 16D and squeeze a stabilized blood sample 12 through the dispensing tip 26D. In one embodiment, the stabilized blood sample 12 may be transferred to a diagnostic instrument such as a blood testing device 60D.
Referring to
During the use of blood transfer device 10E, a lancet device can be used to lance a skin surface S of a patient. Next, the cap 154 is removed to open the blood transfer device 10E and expose the material 16E within the blood transfer device 10E. The blood transfer device 10E is then positioned such that the material 16E is placed adjacent a punctured skin surface S of a patient so that the blood sample 12 can be transferred to the material 16E. For example, the material 16E may touch the punctured skin surface S to soak up the blood sample 12. As the blood 12 is loaded into the material 16E, the blood 12 is exposed to the anticoagulant powder throughout the internal micro pore structure of the material 16E. Once the material 16E is loaded with the blood 12, the cap 154 is connected to the blood transfer device 10E to close the blood transfer device 10E and the material 16E is deformed, e.g., compressed, to squeeze out a stabilized blood sample 12. For example, the blood transfer device 10E can be pushed down on a surface to trigger the internal mechanism within the housing 14E of the blood transfer device 10E to automatically compress the material 16E and squeeze a stabilized blood sample 12 through the dispensing tip 26E. In one embodiment, the stabilized blood sample 12 may be transferred to a diagnostic instrument such as a blood testing device 60E.
Referring to
Referring to
A blood transfer device of the present disclosure offers uniform blood mixing with an anticoagulant throughout micro pores of an open cell foam for small sample volumes such as capillary blood samples obtained from a finger stick. A blood transfer device of the present disclosure could catch blood clots or other contaminants within the pores of the open cell foam and prevent them from being dispensed into a diagnostic sample port. A blood transfer device of the present disclosure enables a simple, low cost design for receiving and dispensing a blood sample. Blood sample management based on a deformable open cell foam may be used and adjusted for capillary, venous, and arterial sample management.
Referring to
In one embodiment, open cell foam material 306 includes pores 312 and is disposed within the housing 304 of the blood transfer device 300. Referring to
The open cell foam material 306 is adapted to receive a blood sample 302 such that the blood sample 302 is mixed with the dry anticoagulant powder 310 which is present inside the open cell foam material 306. In this manner, a stabilized blood sample may travel from the open cell foam material 306 into capillary tube 308 for final metering and dispensing as described in more detail below.
In one embodiment, the open cell foam 306 is treated with an anticoagulant to form a dry anticoagulant powder 310 finely distributed throughout the pores 312 of the open cell foam 306. The open cell foam 306 may be loaded with a blood sample 302. The blood 302 gets soaked into the open cell foam 306 based on capillary principles. As the blood 302 is loaded into the open cell foam 306, the blood 302 is exposed to the anticoagulant powder 310 throughout the internal micro pore structure of the open cell foam 306. The stabilized blood sample 302 may be transferred to a diagnostic instrument such as a blood testing device, a point-of-care testing device, or similar analytical device.
As described above, a method of loading an anticoagulant to the open cell foam material 306 having pores 312 may include soaking the open cell foam material 306 in a liquid solution of the anticoagulant and water; evaporating the water of the liquid solution; and forming a dry anticoagulant powder 310 within the pores 312 of the open cell foam material 306.
The method of the present disclosure enables precisely controlled loading of an anticoagulant into the open cell foam material 306 by soaking it with an anticoagulant and water solution and then drying the open cell foam material 306 to form a finely distributed dry anticoagulant powder 310 throughout the pores 312 of the open cell foam material 306.
Anticoagulants such as Heparin or EDTA (Ethylene Diamine Tetra Acetic Acid) as well as other blood stabilization agents could be introduced into the open cell foam material 306 as a liquid solution by soaking the open cell foam material 306 in the liquid solution of a desired concentration. After evaporating the liquid phase, e.g., evaporating the water from a water and Heparin solution, a dry anticoagulant powder may be formed and finely distributed throughout the internal structure of the open cell foam material 306. For example, the dry anticoagulant powder may be finely distributed throughout the pores 312 of the open cell foam material 306. In a similar manner, the open cell foam material 306 could be treated to provide a hydrophobic, hydrophilic, or reactive internal pore surface.
Referring to
The capillary tube 308 is adapted to receive the blood sample 302 after the blood sample 302 is mixed with the dry anticoagulant powder 310 within the open cell foam material 306. Referring to
In one embodiment, the capillary tube 308 or the housing 304 of the blood transfer device 300 may include fill lines, such as graduations located on a sidewall 350 of blood transfer device 300, for providing an indication as to the level or amount of stabilized blood sample 302 contained within capillary tube 308. Such markings may be provided on an external surface of sidewall 350, an internal surface of sidewall 350, or integrally formed or otherwise within sidewall 350 of blood transfer device 300.
Referring to
Next, referring to
As the blood 302 is loaded into the open cell foam material 306, the blood 302 is exposed to the anticoagulant powder 310 throughout the internal micro pore structure of the open cell foam material 306. Referring to
Referring to
The stabilized blood sample 302 is allowed to fill up the capillary tube 308 to the appropriate marking or fill line, such as the graduations located on a sidewall 350 of blood transfer device 300 as described above. In one embodiment, the length of the capillary tube 308 up to a marking defines the volume of the blood sample collected, e.g., blood metering.
Referring to
The blood transfer device 300 includes an open cell foam material 306 and a capillary tube 308 to collect a blood sample 302, stabilize the blood sample 302, e.g., mix the blood sample 302 with a dry anticoagulant powder 310 within the open cell foam material 306, meter the blood sample 302, and dispense the stabilized blood sample to a diagnostic device.
Capillary blood samples may be transferred by capillary tubes that have an internal wall coated with a dry anticoagulant. Such capillary tubes might result in insufficient blood mixing with the anticoagulant due to the laminar nature of the capillary flow and slow diffusion kinetics of the dry anticoagulant. The blood transfer device 300 of the present disclosure enables more uniform mixing of a capillary blood sample by mixing the blood sample with a dry anticoagulant powder 310 within the open cell foam material 306 before it enters the capillary tube 308 for final dispensing.
Referring to
In one embodiment, open cell foam material 406 includes pores 412 and is disposed within the housing 404 of the blood transfer device 400. Referring to
As described above, the open cell foam material 406 is adapted to receive a blood sample 402 such that the blood sample 402 is mixed with the dry anticoagulant powder 410 which is present inside the open cell foam material 406. In this manner, a stabilized blood sample may travel from the open cell foam material 406 into the second capillary tube 414 for final metering and dispensing as described in more detail below.
In one embodiment, the open cell foam 406 is treated with an anticoagulant to form a dry anticoagulant powder 410 finely distributed throughout the pores 412 of the open cell foam 406. The open cell foam 406 may be loaded with a blood sample 402. The blood sample 402 is transferred to the open cell foam material 406 via the first capillary tube 408. As the blood 402 is loaded into the open cell foam 406, the blood 402 is exposed to the anticoagulant powder 410 throughout the internal micro pore structure of the open cell foam 406. The stabilized blood sample 402 may be transferred to a diagnostic instrument such as a blood testing device, a point-of-care testing device, or similar analytical device.
In one embodiment, the open cell foam material 406 is a soft deformable open cell foam that is inert to blood. In one embodiment, the open cell foam material 406 is a Basotect® foam available from BASF. Such a foam is a Melamine foam which is an open cell foam material consisting of a formaldehyde-melamine-sodium bisulfite copolymer. The Melamine foam is a flexible, hydrophilic open cell foam that is resistant to heat and many organic solvents. In one embodiment, the open cell foam material 406 may be a sponge material.
As described above, a method of loading an anticoagulant to the open cell foam material 406 having pores 412 may include soaking the open cell foam material 406 in a liquid solution of the anticoagulant and water; evaporating the water of the liquid solution; and forming a dry anticoagulant powder 410 within the pores 412 of the open cell foam material 406.
The method of the present disclosure enables precisely controlled loading of an anticoagulant into the open cell foam material 406 by soaking it with an anticoagulant and water solution and then drying the open cell foam material 406 to form a finely distributed dry anticoagulant powder 410 throughout the pores 412 of the open cell foam material 406.
Anticoagulants such as Heparin or EDTA (Ethylene Diamine Tetra Acetic Acid) as well as other blood stabilization agents could be introduced into the open cell foam material 406 as a liquid solution by soaking the open cell foam material 406 in the liquid solution of a desired concentration. After evaporating the liquid phase, e.g., evaporating the water from a water and Heparin solution, a dry anticoagulant powder may be formed and finely distributed throughout the internal structure of the open cell foam material 406. For example, the dry anticoagulant powder may be finely distributed throughout the pores 412 of the open cell foam material 406. In a similar manner, the open cell foam material 406 could be treated to provide a hydrophobic, hydrophilic, or reactive internal pore surface.
Referring to
The first capillary tube 408 includes an inlet 460, a second end 462, and an internal wall surface 464. The first capillary tube 408 is in fluid communication with the open cell foam material 406 and a portion of the first capillary tube 408 is disposed within the housing 404 of the blood transfer device 400. The second end 462 of the first capillary tube 408 is in fluid communication with the open cell foam material 406. In one embodiment, the internal wall surface 464 of the first capillary tube 408 includes an anticoagulant coating.
Referring to
The second capillary tube 414 includes a first end 470, a dispensing tip 472, and an internal wall surface 474. The second capillary tube 414 is in fluid communication with the open cell foam material 406 and a portion of the second capillary tube 414 is disposed within the housing 404 of the blood transfer device 400. The first end 470 of the second capillary tube 414 is in fluid communication with the open cell foam material 406. In one embodiment, the internal wall surface 474 of the second capillary tube 414 includes an anticoagulant coating.
The second capillary tube 414 is adapted to receive the blood sample 402 after the blood sample 402 is mixed with the dry anticoagulant powder 410 within the open cell foam material 406. Referring to
In one embodiment, the second capillary tube 414 or the housing 404 of the blood transfer device 400 may include fill lines, such as graduations located on a sidewall 450 of blood transfer device 400, for providing an indication as to the level or amount of stabilized blood sample 402 contained within second capillary tube 414. Such markings may be provided on an external surface of sidewall 450, an internal surface of sidewall 450, or integrally formed or otherwise within sidewall 450 of blood transfer device 400.
Referring to
Referring to
Next, referring to
As the blood 402 is loaded into the open cell foam material 406 via the first capillary tube 408, the blood 402 is exposed to the anticoagulant powder 410 throughout the internal micro pore structure of the open cell foam material 406. Referring to
Referring to
The stabilized blood sample 402 is allowed to fill up the second capillary tube 414 to the appropriate marking or fill line, such as the graduations located on a sidewall 450 of blood transfer device 400 as described above. In one embodiment, the length of the second capillary tube 414 up to a marking defines the volume of the blood sample collected, e.g., blood metering.
Referring to
The blood transfer device 400 includes an open cell foam material 406 and a first capillary tube 408 and second capillary tube 414 to collect a blood sample 402, stabilize the blood sample 402, e.g., mix the blood sample 402 with a dry anticoagulant powder 410 within the open cell foam material 406, meter the blood sample 402, and dispense the stabilized blood sample to a diagnostic device.
Capillary blood samples may be transferred by capillary tubes that have an internal wall coated with a dry anticoagulant. Such capillary tubes might result in insufficient blood mixing with the anticoagulant due to the laminar nature of the capillary flow and slow diffusion kinetics of the dry anticoagulant. The blood transfer device 400 of the present disclosure enables more uniform mixing of a capillary blood sample by mixing the blood sample with a dry anticoagulant powder 410 within the open cell foam material 406 before it enters the second capillary tube 414 for final dispensing.
In one embodiment, the syringe assembly 500 includes a syringe barrel 506 having a first end 508, a second end 510, and a sidewall 512 extending therebetween and defining an interior 514. Referring to
In one embodiment, the syringe assembly 500 includes a plunger rod 516 and a stopper 518. The plunger rod 516 includes a first end and a second end. The stopper 518 is engaged with the second end 522 of the plunger rod 516 and is slidably disposed within the interior 514 of the syringe barrel 506. The stopper 518 is sized relative to the interior 514 of the syringe barrel 506 to provide sealing engagement with the sidewall 512 of the syringe barrel 506.
The open cell foam material 502 is placed in the syringe barrel 506 for mixing and stabilizing blood. The blood gets collected in the syringe barrel 506 with the open cell foam material 502 embedded inside the syringe barrel 506. The stabilized blood can then be dispensed for analysis. In one embodiment, the syringe assembly is an arterial blood gas syringe and the stabilized blood can be dispensed for blood gas analysis.
While this disclosure has been described as having exemplary designs, the present disclosure can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the disclosure using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this disclosure pertains and which fall within the limits of the appended claims.
This application is a continuation of U.S. application Ser. No. 15/097,725, entitled “Blood Sample Management Using Open Cell Foam” filed Apr. 13, 2016, which is a divisional application of U.S. application Ser. No. 14/861,136, entitled “Blood Sample Management Using Open Cell Foam” filed Sep. 22, 2015 (now U.S. Pat. No. 9,693,723), which claims priority to U.S. Provisional Application Ser. No. 62/063,536, entitled “Blood Sample Management Using Open Cell Foam” filed Oct. 14, 2014, and U.S. Provisional Application Ser. No. 62/207,618, entitled “Blood Sample Management Using Open Cell Foam” filed Aug. 20, 2015, the entire disclosures of each of which are herein incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3626929 | Sanz et al. | Dec 1971 | A |
3819913 | Carter et al. | Jun 1974 | A |
3916205 | Kleinerman | Oct 1975 | A |
3963350 | Watanabe et al. | Jun 1976 | A |
4088448 | Lilja et al. | May 1978 | A |
4125828 | Resnick et al. | Nov 1978 | A |
4133304 | Bailey | Jan 1979 | A |
4133873 | Noller | Jan 1979 | A |
4337222 | Kitajima et al. | Jun 1982 | A |
4501496 | Griffin | Feb 1985 | A |
4703761 | Rathbone et al. | Nov 1987 | A |
4727020 | Recktenwald | Feb 1988 | A |
4751188 | Valet | Jun 1988 | A |
4857735 | Noller | Aug 1989 | A |
4959305 | Woodrum | Sep 1990 | A |
5014718 | Mitchen | May 1991 | A |
5053626 | Tillotson | Oct 1991 | A |
5073857 | Peters et al. | Dec 1991 | A |
5102625 | Milo | Apr 1992 | A |
5134662 | Bacus et al. | Jul 1992 | A |
5159642 | Kosaka | Oct 1992 | A |
5187749 | Sugimoto et al. | Feb 1993 | A |
5196709 | Berndt et al. | Mar 1993 | A |
5200152 | Brown | Apr 1993 | A |
5244021 | Hau | Sep 1993 | A |
5294799 | Aslund et al. | Mar 1994 | A |
5332905 | Brooker et al. | Jul 1994 | A |
5348859 | Brunhouse et al. | Sep 1994 | A |
5385539 | Maynard | Jan 1995 | A |
5489771 | Beach et al. | Feb 1996 | A |
5491343 | Brooker | Feb 1996 | A |
5505212 | Keljmann | Apr 1996 | A |
5528045 | Hoffman et al. | Jun 1996 | A |
5547849 | Baer et al. | Aug 1996 | A |
5556764 | Sizto et al. | Sep 1996 | A |
5592291 | Iida | Jan 1997 | A |
5599668 | Stimpson et al. | Feb 1997 | A |
5627037 | Ward et al. | May 1997 | A |
5661558 | Nogami et al. | Aug 1997 | A |
5674457 | Williamsson et al. | Oct 1997 | A |
5675155 | Pentoney, Jr. et al. | Oct 1997 | A |
5681529 | Taguchi et al. | Oct 1997 | A |
5692503 | Kuenstner | Dec 1997 | A |
5732150 | Zhou et al. | Mar 1998 | A |
5733721 | Hemstreet, III et al. | Mar 1998 | A |
5770158 | Eischen et al. | Jun 1998 | A |
5773301 | Ziegler | Jun 1998 | A |
5851835 | Groner | Dec 1998 | A |
5890828 | Gueret | Apr 1999 | A |
5898487 | Hage | Apr 1999 | A |
5933233 | Gunther | Aug 1999 | A |
5938439 | Mertins et al. | Aug 1999 | A |
6043880 | Andrews et al. | Mar 2000 | A |
6064474 | Lee et al. | May 2000 | A |
6064897 | Lindberg et al. | May 2000 | A |
6094592 | Yorkey et al. | Jul 2000 | A |
6103197 | Werner | Aug 2000 | A |
6154282 | Lilge et al. | Nov 2000 | A |
6159740 | Hudson et al. | Dec 2000 | A |
6181418 | Palumbo et al. | Jan 2001 | B1 |
6187592 | Gourley | Feb 2001 | B1 |
6214629 | Freitag et al. | Apr 2001 | B1 |
6226347 | Golenhofen | May 2001 | B1 |
6262798 | Shepherd et al. | Jul 2001 | B1 |
6294094 | Muller et al. | Sep 2001 | B1 |
6305804 | Rice et al. | Oct 2001 | B1 |
6342376 | Kozian et al. | Jan 2002 | B1 |
6350613 | Wardlaw et al. | Feb 2002 | B1 |
6410341 | Freitag et al. | Jun 2002 | B1 |
6448018 | Nakayama et al. | Sep 2002 | B1 |
6453060 | Riley et al. | Sep 2002 | B1 |
6477394 | Rice et al. | Nov 2002 | B2 |
6479299 | Parce et al. | Nov 2002 | B1 |
6493567 | Krivitski et al. | Dec 2002 | B1 |
6519025 | Shepherd et al. | Feb 2003 | B2 |
6563585 | Rao et al. | May 2003 | B1 |
6594075 | Kanao et al. | Jul 2003 | B1 |
6611320 | Lindberg et al. | Aug 2003 | B1 |
6612111 | Hodges et al. | Sep 2003 | B1 |
6638769 | Lilja et al. | Oct 2003 | B2 |
6665060 | Zahniser et al. | Dec 2003 | B1 |
6696240 | Kloepfer et al. | Feb 2004 | B1 |
6716588 | Sammak et al. | Apr 2004 | B2 |
6723290 | Wardlaw | Apr 2004 | B1 |
6740527 | Wong et al. | May 2004 | B1 |
6825921 | Modlin et al. | Nov 2004 | B1 |
6828567 | Amirkhanian et al. | Dec 2004 | B2 |
6831733 | Pettersson et al. | Dec 2004 | B2 |
6858400 | Bristow | Feb 2005 | B2 |
6862534 | Sterling et al. | Mar 2005 | B2 |
6869405 | Marsden | Mar 2005 | B2 |
6869570 | Wardlaw | Mar 2005 | B2 |
6898458 | Zeng et al. | May 2005 | B2 |
6960165 | Ueno et al. | Nov 2005 | B2 |
6985224 | Hart | Jan 2006 | B2 |
6999173 | Kleinfeld et al. | Feb 2006 | B2 |
7075628 | Shepherd et al. | Jul 2006 | B2 |
7094562 | Bittner | Aug 2006 | B2 |
7096124 | Sterling et al. | Aug 2006 | B2 |
7115841 | Zeng et al. | Oct 2006 | B2 |
7133545 | Douglass et al. | Nov 2006 | B2 |
7139073 | Terada | Nov 2006 | B1 |
7146372 | Bacus et al. | Dec 2006 | B2 |
7149332 | Bacus et al. | Dec 2006 | B2 |
7271912 | Sterling et al. | Sep 2007 | B2 |
7279134 | Chan et al. | Oct 2007 | B2 |
7303922 | Jeng et al. | Dec 2007 | B2 |
7319894 | Higgins | Jan 2008 | B2 |
7324674 | Ozawa et al. | Jan 2008 | B2 |
7378054 | Karmali | May 2008 | B2 |
7420660 | Muller | Sep 2008 | B2 |
7426407 | Higgins | Sep 2008 | B2 |
7477382 | Grey et al. | Jan 2009 | B2 |
7500569 | Manoussakis et al. | Mar 2009 | B2 |
7515268 | Ayliffe et al. | Apr 2009 | B1 |
7518727 | Pentoney, Jr. et al. | Apr 2009 | B2 |
7539335 | Fukuyama | May 2009 | B2 |
7560073 | Peters et al. | Jul 2009 | B1 |
7625712 | Paul et al. | Dec 2009 | B2 |
7630063 | Padmanabhan et al. | Dec 2009 | B2 |
7674598 | Paul et al. | Mar 2010 | B2 |
7738094 | Goldberg | Jun 2010 | B2 |
7762946 | Sugimoto | Jul 2010 | B2 |
7781226 | McDevitt et al. | Aug 2010 | B2 |
7790464 | Tarasev | Sep 2010 | B2 |
7816135 | Goldberg | Oct 2010 | B2 |
7826728 | Konno et al. | Nov 2010 | B2 |
7854891 | Yamamoto et al. | Dec 2010 | B2 |
7892551 | Glencross | Feb 2011 | B2 |
7903241 | Wardlaw et al. | Mar 2011 | B2 |
7952692 | Primack et al. | May 2011 | B2 |
8009894 | Lindberg et al. | Aug 2011 | B2 |
8125623 | Munger et al. | Feb 2012 | B2 |
8224058 | Lindberg et al. | Jul 2012 | B2 |
8244021 | Lett et al. | Aug 2012 | B2 |
8306594 | Paseman et al. | Nov 2012 | B2 |
8353848 | Long et al. | Jan 2013 | B2 |
8377398 | McDevitt et al. | Feb 2013 | B2 |
8406859 | Zuzak et al. | Mar 2013 | B2 |
8483789 | Higgins | Jul 2013 | B2 |
8488903 | Higuchi | Jul 2013 | B2 |
8541227 | Christensen et al. | Sep 2013 | B2 |
8630016 | Swenson et al. | Jan 2014 | B2 |
9693723 | Ivosevic | Jul 2017 | B2 |
20020143298 | Marsden | Oct 2002 | A1 |
20020164825 | Chen | Nov 2002 | A1 |
20030123047 | Pettersson et al. | Jul 2003 | A1 |
20030152927 | Jakobsen et al. | Aug 2003 | A1 |
20030170613 | Straus | Sep 2003 | A1 |
20030206828 | Bell | Nov 2003 | A1 |
20030230728 | Dai et al. | Dec 2003 | A1 |
20040224329 | Gjerde et al. | Nov 2004 | A1 |
20050054949 | McKinnon et al. | Mar 2005 | A1 |
20050139547 | Manoussakis et al. | Jun 2005 | A1 |
20050142565 | Samper et al. | Jun 2005 | A1 |
20050190058 | Call | Sep 2005 | A1 |
20050232813 | Karmali | Oct 2005 | A1 |
20060020531 | Veeneman et al. | Jan 2006 | A1 |
20060024756 | Tibbe et al. | Feb 2006 | A1 |
20060060531 | Coville et al. | Mar 2006 | A1 |
20060241495 | Kurtz | Oct 2006 | A1 |
20060252079 | Oldham et al. | Nov 2006 | A1 |
20070132994 | Kobayashi et al. | Jun 2007 | A1 |
20070178009 | Sakaino et al. | Aug 2007 | A1 |
20080190220 | Backes et al. | Aug 2008 | A1 |
20080203319 | Pentoney et al. | Aug 2008 | A1 |
20080208078 | Neel | Aug 2008 | A1 |
20080268469 | Srienc et al. | Oct 2008 | A1 |
20090024060 | Darrigrand et al. | Jan 2009 | A1 |
20090075324 | Pettersson | Mar 2009 | A1 |
20090107903 | Dassa | Apr 2009 | A1 |
20090130646 | Fletcher et al. | May 2009 | A1 |
20090173685 | Imai et al. | Jul 2009 | A1 |
20090181411 | Battrell et al. | Jul 2009 | A1 |
20090259145 | Bartfeld et al. | Oct 2009 | A1 |
20100285520 | Halverson et al. | Nov 2010 | A1 |
20100291599 | Tague, Jr. et al. | Nov 2010 | A1 |
20100314461 | Gruenbacher et al. | Dec 2010 | A1 |
20110106046 | Hiranuma et al. | May 2011 | A1 |
20110118139 | Mehta et al. | May 2011 | A1 |
20110159457 | Offermann | Jun 2011 | A1 |
20110159533 | Karkouche | Jun 2011 | A1 |
20120016265 | Peterson et al. | Jan 2012 | A1 |
20120016307 | Burkholz et al. | Jan 2012 | A1 |
20120123297 | Brancazio | May 2012 | A1 |
20130045529 | Goldberg et al. | Feb 2013 | A1 |
20130076019 | Takemoto | Mar 2013 | A1 |
20130162990 | Kobayashi et al. | Jun 2013 | A1 |
20140073990 | Holmes et al. | Mar 2014 | A1 |
20140093896 | Mongale et al. | Apr 2014 | A1 |
20140176939 | Shah | Jun 2014 | A1 |
20140200154 | Sugarman et al. | Jul 2014 | A1 |
20140269160 | Chee Mun | Sep 2014 | A1 |
20140309555 | Gelfand | Oct 2014 | A1 |
20150125882 | Bornheimer et al. | May 2015 | A1 |
20150125883 | Gordon et al. | May 2015 | A1 |
20150132789 | Bornheimer et al. | May 2015 | A1 |
20160100783 | Ivosevic et al. | Apr 2016 | A1 |
Number | Date | Country |
---|---|---|
101036591 | Sep 2007 | CN |
102119017 | Jul 2011 | CN |
202141619 | Feb 2012 | CN |
103068307 | Apr 2013 | CN |
202928839 | May 2013 | CN |
203785945 | Aug 2014 | CN |
205181357 | Apr 2016 | CN |
205317561 | Jun 2016 | CN |
0219053 | Apr 1987 | EP |
0545500 | Jun 1993 | EP |
0681177 | Nov 1995 | EP |
0737855 | Oct 1996 | EP |
0744600 | Nov 1996 | EP |
0788615 | Aug 1997 | EP |
0800074 | Oct 1997 | EP |
0818682 | Jan 1998 | EP |
0821784 | Nov 1998 | EP |
0959346 | Nov 1999 | EP |
0969279 | Jan 2000 | EP |
0663070 | May 2000 | EP |
0681177 | Jul 2000 | EP |
0744600 | Aug 2001 | EP |
0818682 | Oct 2001 | EP |
0809807 | Jul 2002 | EP |
0788615 | Sep 2002 | EP |
0800074 | Jul 2003 | EP |
1324021 | Jul 2003 | EP |
0969279 | Oct 2003 | EP |
1347702 | Oct 2003 | EP |
1456649 | Jun 2006 | EP |
1698883 | Sep 2006 | EP |
1701150 | Sep 2006 | EP |
1767935 | Mar 2007 | EP |
1813349 | Aug 2007 | EP |
1324021 | Jan 2008 | EP |
1924195 | May 2008 | EP |
1990638 | Nov 2008 | EP |
2016390 | Jan 2009 | EP |
2041549 | Apr 2009 | EP |
2083687 | Aug 2009 | EP |
1405073 | Mar 2010 | EP |
2232442 | Sep 2010 | EP |
1698883 | Jan 2011 | EP |
2298407 | Mar 2011 | EP |
2016390 | Apr 2013 | EP |
2586370 | May 2013 | EP |
2605020 | Jun 2013 | EP |
1558934 | Jul 2013 | EP |
2676606 | Dec 2013 | EP |
1595388 | Aug 1981 | GB |
62181056 | Aug 1987 | JP |
10323341 | Dec 1998 | JP |
11318871 | Nov 1999 | JP |
200074906 | Mar 2000 | JP |
2000176006 | Jun 2000 | JP |
2000262271 | Sep 2000 | JP |
200188098 | Apr 2001 | JP |
2001324500 | Nov 2001 | JP |
2002506208 | Feb 2002 | JP |
2002516982 | Jun 2002 | JP |
200319126 | Jan 2003 | JP |
200517280 | Jan 2005 | JP |
200517281 | Jan 2005 | JP |
2005006821 | Jan 2005 | JP |
2007518978 | Jul 2007 | JP |
2008525768 | Jul 2008 | JP |
4255556 | Apr 2009 | JP |
2009525819 | Jul 2009 | JP |
201195157 | May 2011 | JP |
2011133235 | Jul 2011 | JP |
2011529573 | Dec 2011 | JP |
2012137493 | Jul 2012 | JP |
2013096797 | May 2013 | JP |
6909366 | Jan 1970 | NL |
9920998 | Apr 1999 | WO |
9945384 | Sep 1999 | WO |
0028297 | May 2000 | WO |
0244729 | Jun 2002 | WO |
0250518 | Jun 2002 | WO |
03036290 | May 2003 | WO |
WO 03094770 | Nov 2003 | WO |
2004100887 | Nov 2004 | WO |
2005100539 | Oct 2005 | WO |
2006047831 | May 2006 | WO |
2006096126 | Sep 2006 | WO |
2006119368 | Nov 2006 | WO |
2006124756 | Nov 2006 | WO |
2007012675 | Feb 2007 | WO |
2007033318 | Mar 2007 | WO |
2007051861 | May 2007 | WO |
2007111555 | Oct 2007 | WO |
2007129948 | Nov 2007 | WO |
2007145328 | Dec 2007 | WO |
2008002462 | Jan 2008 | WO |
2008010761 | Jan 2008 | WO |
2008037068 | Apr 2008 | WO |
2008103992 | Aug 2008 | WO |
2009091318 | Jul 2009 | WO |
2009155612 | Dec 2009 | WO |
2010003518 | Jan 2010 | WO |
2010085658 | Jul 2010 | WO |
2011133540 | Oct 2011 | WO |
2012117648 | Sep 2012 | WO |
2013075031 | May 2013 | WO |
2013128177 | Sep 2013 | WO |
Number | Date | Country | |
---|---|---|---|
20200146604 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
62063536 | Oct 2014 | US | |
62207618 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14861136 | Sep 2015 | US |
Child | 15097725 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15097725 | Apr 2016 | US |
Child | 16747243 | US |